Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Aspirin  COVID-19 treatment studies for Aspirin  C19 studies: Aspirin  Aspirin   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent: 
0 0.5 1 1.5 2+ Mortality 4% Improvement Relative Risk Mortality (b) 17% Ventilation 5% Discharge 6% Discharge (b) 16% Hospitalization time 11% no CI c19aspirin.com RECOVERY et al. RECOVERY Aspirin RCT LATE TREATMENT Favors aspirin Favors control
RECOVERY, 14,892 patient aspirin late treatment RCT: 4% lower mortality [p=0.35], 5% lower ventilation [p=0.32], 6% higher hospital discharge [p=0.006], and 11% shorter hospitalization https://c19p.org/recoverye
copied to clipboard
Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
RECOVERY Collaborative Group, The Lancet, doi:10.1016/S0140-6736(21)01825-0, RECOVERY
18 Nov 2021    Source   PDF   Share   Tweet
RCT 14,892 late stage patients, 7,351 treated with aspirin, showing slightly improved discharge and hospitalization time, and no significant difference for mortality.
Results are limited due to low dose (150mg daily), very late treatment (9 days post symptom onset), and 96% concurrent use of low molecular weight heparin. Greater benefits were seen for non-LMWH patients, and for very late (<= 7 days from onset) vs. extremely late (>7 days) treatment. For more discussion see [twitter.com].
risk of death, 4.0% lower, RR 0.96, p = 0.35, treatment 7,351, control 7,541.
risk of death, 17.0% lower, RR 0.83, p = 0.35, treatment 7,351, control 7,541, non-LMWH.
risk of mechanical ventilation, 5.0% lower, RR 0.95, p = 0.32, treatment 7,351, control 7,541.
risk of no hospital discharge, 5.7% lower, RR 0.94, p = 0.006, treatment 7,351, control 7,541, inverted to make RR<1 favor treatment.
risk of no hospital discharge, 16.0% lower, RR 0.84, p = 0.04, treatment 7,351, control 7,541, inverted to make RR<1 favor treatment, non-LMWH.
hospitalization time, 11.1% lower, relative time 0.89, treatment 7,351, control 7,541.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
RECOVERY et al., 18 Nov 2021, Randomized Controlled Trial, multiple countries, peer-reviewed, 1 author, study period 1 November, 2020 - 21 March, 2021, average treatment delay 9.0 days, RECOVERY trial.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperAspirinAll
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit